JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 27, 2004; DOI: 10.1124/jpet.103.062695


0022-3565/04/3092-578-586$20.00
JPET 309:578-586, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.062695v1
309/2/578    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson-Davis, K. L.
Right arrow Articles by Wilkins, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson-Davis, K. L.
Right arrow Articles by Wilkins, D. G.

NEUROPHARMACOLOGY

Alterations in Vesicular Dopamine Uptake Contribute to Tolerance to the Neurotoxic Effects of Methamphetamine

Kamisha L. Johnson-Davis, Jannine G. Truong, Annette E. Fleckenstein, and Diana G. Wilkins

Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah

Previous studies demonstrated that tolerance to the long-term neurotoxic effects of methamphetamine on dopamine neurons could be induced by pretreating with multiple injections of escalating doses of methamphetamine. The mechanism(s) underlying this tolerance phenomenon is unknown. Some recent studies suggested that aberrant vesicular monoamine transporter-2 (VMAT-2) and dopamine transporter function contribute to neurotoxic effects of methamphetamine. Hence, the purpose of this study was to explore the role of the VMAT-2 and dopamine transporter in the induction of tolerance to the longterm persistent dopaminergic deficits caused by methamphetamine. A second purpose was to investigate the potential role of hyperthermia and alterations in brain methamphetamine distribution in this tolerance. Results revealed that the methamphetamine pretreatment regimen attenuated both the acute methamphetamine-induced decrease in VMAT-2 function 2 h after the methamphetamine challenge administration and its resulting persistent dopamine deficits without attenuating the acute methamphetamine-induced decreases in dopamine transporter uptake. Furthermore, pretreatment with methamphetamine prior to a high-dose methamphetamine challenge administration also attenuated the acute methamphetamine-induced redistribution of VMAT-2 immunoreactivity within the nerve terminal. This protection was not due to alterations in concentration of methamphetamine in the brain because both the methamphetamine- and saline-pretreated rats had similar amounts of methamphetamine and amphetamine at 30 min to 2 h after the last methamphetamine challenge injection. In summary, these data are the first to demonstrate an association between the prevention of acute alterations in vesicular dopamine uptake and the development of tolerance to the neurotoxic effects of methamphetamine.


Received for publication November 6, 2003
Accepted January 23, 2004.

Address correspondence to: Dr. Diana G. Wilkins, Codirector, Center for Human Toxicology, Research Associate Professor, Department of Pharmacology and Toxicology, University of Utah, 20 South 2030 East, Room 490, Salt Lake City, UT 84112-9457. Email: dwilkins{at}alanine.pharm.utah.edu




This article has been cited by other articles:


Home page
J. Neurosci.Home page
H. A. Boger, L. D. Middaugh, K. S. Patrick, S. Ramamoorthy, E. D. Denehy, H. Zhu, A. M. Pacchioni, A.-C. Granholm, and J. F. McGinty
Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice
J. Neurosci., August 15, 2007; 27(33): 8816 - 8825.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
Z. Lin, D. Walther, X.-Y. Yu, S. Li, T. Drgon, and G. R. Uhl
SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism
Hum. Mol. Genet., May 15, 2005; 14(10): 1393 - 1404.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.